Patiromer

Patiromer is an orally active, selective and non-absorbable intestinal potassium (K+) polymer binder that reversibly binds potassium ions in exchange for calcium (Ca2+) . Patiromer can rapidly and continuously reduce serum potassium levels, maintain a normal blood potassium state, and reduce serum aldosterone levels. Patiromer also increases fecal potassium excretion. Patiromer is mainly used in the study of hyperkalemia associated with diseases such as chronic kidney disease, diabetes, and heart failure, and is particularly suitable for improving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy[1][2][3].

Product Specifications

CAS Number

[1208912-84-8]

UNSPSC

12352211

Target

Interleukin Related; JAK; STAT

Type

Reference compound

Related Pathways

Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/patiromer.html

Purity

95.0

Solubility

H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CCC(C([O-])=O)(F)CC(C1=CC=CC=C1)CC(CCCCC(C)CC)C.CC(CC)C.[Ca+2].[p].[p].[n].[m].[n].[1/2]

Molecular Formula

(C10H10.C8H14.C3H3FO2.1/2Ca) x

References & Citations

[1]Weir MR, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15;372 (3) :211-21.|[2]Iyer SPN, et al. Pharmacodynamic effects of the K+ binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats. Physiol Rep. 2020 Sep;8 (18) :e14572.|[3]Colbert GB, et al. Patiromer for the treatment of hyperkalemia. Expert Rev Clin Pharmacol. 2020 Jun;13 (6) :563-570.